Shifting emphasis from pharmacogenomics to theragnostics.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16900136.
- Also identified by PMC identifier 7096916.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
What will be the role of theragnostic patents in upstream and downstream biomarker research?
Medical subject headings
- Drug Delivery Systems
- Drug Design
- Pharmacogenetics